8-K: Beyond Air Reports Strong Preliminary Q3 Revenue Growth

Beyond Air announced preliminary unaudited revenue of $2.3 million for the quarter ended September 30, 2026, marking significant sequential and year-over-year growth.

Summary

• Beyond Air reported preliminary, unaudited revenue of approximately $2.3 million for the third quarter of 2026.
• This represents a 30% increase from the previous quarter (ended June 30, 2026) and a 27% increase compared to the same quarter last year.
• The company reaffirmed its revenue guidance of $8 million for calendar year 2026 and $16 million to $18 million for calendar year 2027.
• The preliminary revenue is attributed to the successful commercial execution strategy for the first-generation LungFit PH system.
• The second-generation LungFit PH system is still under FDA review, with anticipated demand increase upon approval.
• Complete financial results for the quarter are expected in November 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating strong sequential and year-over-year revenue growth and reaffirmation of future guidance, despite the preliminary nature of the reported figures.

Positives

• Preliminary revenue of $2.3 million for Q3 2026 is the highest quarterly revenue reported.
• Achieved approximately 30% sequential quarterly growth.
• Achieved approximately 27% growth over the same period last year.
• Reaffirmed revenue guidance of $8 million for CY2026.
• Reaffirmed revenue guidance of $16 million to $18 million for CY2027.
• Continued adoption of the first-generation LungFit PH system.
• Enhanced commercial execution strategy for LungFit PH is showing positive results.

Negatives

• The preliminary revenue figures are unaudited and subject to completion of financial closing procedures.
• Actual reported revenue may differ materially from these preliminary estimates.
• The second-generation LungFit PH system is still under FDA review, with no definitive timeline for approval.

Risks

• The preliminary revenue figures are unaudited and subject to change upon completion of financial closing procedures.
• Actual revenue may differ materially from preliminary estimates.
• The second-generation LungFit PH system's approval by the FDA is pending and may not occur in a timely manner or at all.
• Market acceptance of products and competition in the nitric oxide market.
• The company's ability to achieve its revenue guidance, which is based on assumptions that may not be realized.
• The company's ability to obtain necessary financing and satisfy debt obligations.
• Maintaining the listing of its common stock on The Nasdaq Stock Market.

Future Outlook

The company reaffirms its revenue guidance of $8 million for calendar year 2026 and $16 million to $18 million for calendar year 2027. The 2027 guidance includes anticipated revenue from the second-generation LungFit PH system, pending FDA approval. Significant demand increase is expected following FDA approval of the second-generation system.

Management Comments

• "Our strong revenue growth in the quarter ended September 30, 2026 reflects continued adoption of LungFit PH and the value hospitals see in our cylinder-free nitric oxide technology," said Robert Goodman, Chief Executive Officer of Beyond Air.
• "Over the years, we have refined our first-generation system through a series of enhancements and improvements for ease of use."
• "The first-generation LungFit PH has established a strong track record of reliable nitric oxide delivery and has become a trusted system among our hospital customers."
• "Our second-generation system remains under review by the FDA, and we expect demand for the LungFit PH platform to increase significantly following FDA approval."
• "We continue to be pleased with the progress we are seeing with the ongoing PMA supplement process."
• "Adding transport capability will qualify Beyond Air as a single source nitric oxide provider, which is the current standard across most U.S. hospital systems."

Industry Context

StockSavvy.ai notes that Beyond Air's focus on cylinder-free nitric oxide delivery systems addresses a key logistical and safety challenge in hospitals, potentially offering significant advantages over traditional cylinder-based systems. The ongoing FDA review of their second-generation system is critical for expanding their market reach and competitive positioning.

Stakeholder Impact

• Shareholders: Positive impact from strong preliminary revenue growth and reaffirmed guidance, suggesting potential for increased company value.
• Hospitals/Customers: Benefit from the continued adoption and value of the LungFit PH system, with potential for enhanced capabilities upon second-generation system approval.
• Employees: Potential for growth and stability within the company due to positive financial performance and outlook.

Next Steps

• Report complete financial results for the quarter ended September 30, 2026 in November 2026.
• Await FDA review and potential approval of the second-generation LungFit PH system.
• Continue to execute the commercial strategy for the first-generation LungFit PH system.

Key Dates

Recommendation

The preliminary results show positive growth and reaffirmed guidance, which is encouraging. However, the reliance on unaudited figures and the pending FDA approval for the second-generation system introduce a degree of uncertainty. A 'hold' recommendation is appropriate pending the release of audited financial results and further clarity on the FDA approval timeline.

Keywords

LungFit PH, Nitric Oxide, Medical Device, Revenue Guidance, FDA Review, Preliminary Revenue, Commercial Execution, Healthcare